Ditchcarbon
  • Contact
  1. Organizations
  2. Par Pharmaceutical, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 18 days ago

Par Pharmaceutical, Inc. Sustainability Profile

Company website

Par Pharmaceutical, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1978, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals. With a strong focus on high-quality, affordable medications, Par Pharmaceutical serves a diverse range of therapeutic areas, including oncology, pain management, and anti-infectives. The company is recognised for its commitment to innovation, particularly in the production of complex generics and niche products that meet specific patient needs. Par Pharmaceutical has achieved significant milestones, including strategic partnerships and a robust pipeline of products that enhance its market position. With a dedication to excellence and patient care, Par Pharmaceutical continues to make a meaningful impact in the healthcare landscape.

DitchCarbon Score

How does Par Pharmaceutical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

33

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Par Pharmaceutical, Inc.'s score of 33 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.

53%

Let us know if this data was useful to you

Par Pharmaceutical, Inc.'s reported carbon emissions

Inherited from Endo Inc.

Par Pharmaceutical, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Endo Inc., which means that any emissions data or climate commitments may be inherited from its parent organisation. As of now, there are no documented reduction targets or climate pledges specific to Par Pharmaceutical. The absence of specific emissions data suggests that the company may be in the early stages of developing its climate strategy or reporting framework. Given its relationship with Endo Inc., any relevant climate initiatives or emissions data would likely be aligned with the broader commitments of the parent company. However, without specific figures or targets from Par Pharmaceutical, it is challenging to provide a detailed overview of its carbon footprint or climate commitments. In summary, while Par Pharmaceutical, Inc. does not currently report specific emissions data or reduction targets, it is positioned within a corporate structure that may influence its future climate strategies.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920202021202220232024
Scope 1
27,475,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
37,395,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-

How Carbon Intensive is Par Pharmaceutical, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Par Pharmaceutical, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Par Pharmaceutical, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Par Pharmaceutical, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Par Pharmaceutical, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Par Pharmaceutical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Par Pharmaceutical, Inc.'s Emissions with Industry Peers

Allergan

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Alvogen, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Sandoz Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 19 days ago

Teligent, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Impax Laboratories, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Viatris

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy